Mylotarg and Faeces discolored - a phase IV clinical study of FDA data

Summary:

Faeces discolored is reported as a side effect among people who take Mylotarg (gemtuzumab ozogamicin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Cytarabine, and have Acute myeloid leukaemia.

The phase IV clinical study analyzes which people have Faeces discolored when taking Mylotarg. It is created by eHealthMe based on reports of 4,133 people who have side effects when taking Mylotarg from the FDA, and is updated regularly.

What is Mylotarg?

Mylotarg has active ingredients of gemtuzumab ozogamicin. eHealthMe is studying from 4,134 Mylotarg users. Check the latest studies of Mylotarg.

What is Faeces discolored?

Faeces discolored is found to be associated with 1,248 drugs and 1,834 conditions by eHealthMe. Check the latest studies of Faeces discolored.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

4,133 people reported to have side effects when taking Mylotarg.
Among them, 12 people (0.29%) have Faeces discolored.

Among these 12 people:

How long have people been on Mylotarg when they have Faeces discolored? *

What is the gender of people who have Faeces discolored when taking Mylotarg? *

female: 58.33 %
male: 41.67 %

What is the age of people who have Faeces discolored when taking Mylotarg? *

What are other drugs people take besides Mylotarg? *

What are other side effects people have besides Faeces discolored? *

Fever: 8 people, 66.67%
Febrile Neutropenia (fever with reduced white blood cells): 7 people, 58.33%
Thrombocytopenia (decrease of platelets in blood): 6 people, 50.00%
Ascites (accumulation of fluid in the abdominal cavity): 5 people, 41.67%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 5 people, 41.67%
Anaemia (lack of blood): 5 people, 41.67%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 5 people, 41.67%
Bleeding Disorders: 5 people, 41.67%
Infection: 5 people, 41.67%
Blood Bilirubin Increased: 5 people, 41.67%

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 8 people, 66.67%
Iron Overload: 2 people, 16.67%
Cardiac Disorder: 1 person, 8.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Mylotarg and have Faeces discolored?

- Check whether Faeces discolored is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mylotarg:

Mylotarg (4,134 reports)

Browse all side effects of Mylotarg:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Faeces discolored:

Faeces discolored (1,248 drugs)

Browse all the conditions that are associated with Faeces discolored:

Faeces discolored (1,834 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gemtuzumab ozogamicin (the active ingredients of Mylotarg) and Mylotarg (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.